Oral Inhibitor Zoldonrasib Shows Antitumor Activity in Previously Treated KRAS G12D-Mutated NSCLC Patients

A novel oral inhibitor, Zoldonrasib, is showing potential in treating non-small cell lung cancer (NSCLC). Early trials revealed that the drug, which selectively targets the KRAS G12D mutation, demonstrated a manageable safety profile and early signs of antitumor activity in patients who had already undergone previous treatments. The findings suggest Zoldonrasib may represent a new therapeutic avenue for individuals with NSCLC who have limited treatment options. Specifically, the research focused on patients with previously treated NSCLC who received Zoldonrasib orally. Researchers noted the drug’s ability to selectively inhibit the KRAS G12D mutation, a common driver of tumor growth in this type of cancer. The trials monitored the drug’s safety and also assessed its impact on tumor activity. The results indicated that Zoldonrasib was well-tolerated and showed initial evidence of shrinking tumors in this patient population.

Newsflash | Powered by GeneOnline AI
Date: April 27, 2025

Related posts:

Study Reveals Cognitive Decline Linked to Low-Normal Vitamin B12 Levels Trump Executive Order Aims to Streamline Domestic Drug Production by Reducing Regulatory Obstacles Medigi CEO: AI and Automation Streamline Patient Access to Biosimilars and Cell & Gene Therapies Pharmaceutical Industry Sees Personnel Shifts: New Hires, Departures, Promotions and Transfers Reflect Workforce Adjustments

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後